PortViewPortView
Cardio Diagnostics logo

Cardio Diagnostics (CDIOW) Stock Analysis

NASDAQHealthcareBiotechnology

$0.02-2.99%
1-year price historyRange $0.01 – $0.05
52-week range$0.02
$0.01$0.02

What Cardio Diagnostics does

Founded in Chicago, Illinois, in 2017, Cardio Diagnostics Holdings, Inc. specializes in the creation and market introduction of clinical tests. These diagnostic tools leverage epigenetics to assess cardiovascular disease risk. Among its offerings is Epi+Gen CHD, a test designed to predict the risk of symptomatic coronary heart disease over a three-year timeframe.

Key metrics

Market cap
$4.25M
EPS (TTM)
$-3.71
Beta
2.18
Dividend yield
0.00%
Revenue / share
$0.00
50-day avg
$0.02
200-day avg
$0.02
52-week high
$0.02
52-week low
$0.01
CEO
Meeshanthini V. Dogan

ETFs linked to CDIOW

Broad-market and Healthcare sector ETFs an investor holding Cardio Diagnostics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how CDIOW fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze CDIOW in PortView →

Similar companies

Frequently asked questions

What is the ticker symbol for Cardio Diagnostics?
Cardio Diagnostics trades under the ticker CDIOW on NASDAQ.
Which exchange is CDIOW listed on?
CDIOW is listed on NASDAQ.
What sector does Cardio Diagnostics operate in?
Cardio Diagnostics is classified in the Healthcare sector (Biotechnology industry).
How can PortView help analyze CDIOW in a portfolio?
PortView shows CDIOW's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.